Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders
VIENNA–(BUSINESS WIRE)–Proxygen, a leader in the discovery and development of molecular glue degraders, announced today that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. Proxygen is eligible to receive up to €495 million ($554 million at the average USD/EUR FX rate of Q1 2022) in continuous R&D funding, … [Read more…]